Human HLA-A*11:01&B2M&EGFR L858R (KITDFGRAK) Monomer Protein
Catalog No: EGFRL858R-HP001
- Species
- Human
- Expression System
- E. coli
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Human HLA-A*11:01&B2M&EGFR L858R (KITDFGRAK) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and KITDFGRAK peptide (accession: AAV53343.1(HLA-A*11:01) & P61769(B2M) &KITDFGRAK).
Product Details
- Molecular Aliases
- ErbB; EC 2.7.10; EC 2.7.10.1; EGFR; mENA; LEGFR; ERBB; ERBB1; HER1; PIG61; NISBD2
- Protein Length
- Gly25-Thr305
- Expression System
- E. coli
- Theoretical Molecular Weight
- The protein has a predicted MW of 35.36 kDa (HLA-A*11:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Supplied as 0.22 μm filtered solution in 20mM Tris, 200mM NaCl (pH 8.0).
- State
- Liquid
- Storage Conditions
- Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Data Display
Human HLA-A*11:01&B2M&EGFR L858R (KITDFGRAK) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human HLA-A*11:01&B2M&EGFR L858R (KITDFGRAK) Monomer is greater than 95% as determined by SEC-HPLC.
Immobilized Human HLA-A*11:01&B2M&EGFR L858R (KITDFGRAK) Monomer, His Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for HLA-A*11:01&B2M&EGFR TCR with the EC50 of 2.33μg/ml determined by ELISA.
Background
The epidermal growth factor receptor is a transmembrane protein that is a receptor for members of the epidermal growth factor family of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR, HER2/neu, Her 3 and Her 4. Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses.
References
- (1) Seshacharyulu P, Ponnusamy M P, Haridas D, et al. Targeting the EGFR signaling pathway in cancer therapy[J]. Expert Opinion on Therapeutic Targets, 2012.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.